Generic Oncology Drugs Market Size & Industry Analysis By 2027

report image

Generic Oncology Drugs Market to 2027 - Global Analysis and Forecasts by Molecular Type (Large Molecule, Small Molecule); Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Kidney Cancer, Cervical Cancer, Others), and Geography

Publication Month: Aug 2019 | Report Code: TIPRE00006393 | No. of Pages: 152 | Category: Pharmaceuticals | Status: Published

The Generic Oncology Drugs in healthcare market was valued at US$ 21,200.00 million in 2018 and it is projected to reach US$ 36,029.60 million by 2027; it is expected to grow at a CAGR of 6.3% from 2019 to 2027.

Generic Oncology Drugs in healthcare is the use of machine-learning algorithms and software to analyze, process and present complex medical and health care data. It has been widely used to support clinical decisions, improve workflows and predict health outcomes. Thus, wide application of AI in the healthcare sector is likely to propel the growth of the market. The growth of the Generic Oncology Drugs in healthcare market is attributed to the increasing prevalence of cancer across the globe, growing generic drug launches and benefits offered by the generic drugs are likely to boost the market growth, whereas, inclination towards the personalized medicine for cancer is likely to be a prevalent trend in the future years.

The Generic Oncology Drugs in healthcare market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Lucrative Regions for Generic Oncology Drugs in Healthcare Market



Lucrative Regions for Generic Oncology Drugs in Healthcare Market

Get more information on this report :

Market Insights

Growing Applications of Generic Oncology Drugs in Healthcare to Drive Generic Oncology Drugs in Healthcare Market Growth

Cancer is one of the leading cause of deaths across the globe and is extremely affecting the quality of life. Thus, cancer will be burden on society if not diagnosed and treated on time. According to the World Health Organization in 2018, approximately, 9.6 million deaths across the globe were due to cancer. Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases will be diagnosed in the US.

Additionally, cancer is found to be common in European countries as well. As per the Cancer Research UK, in 2016, around 163,444 deaths in UK were due to cancer. 

Furthermore, Asia Pacific region is also facing the problem of growing prevalence of cancer. The top 15 countries with

Cancer prevalence are: Japan, Taiwan, Singapore, South Korea, Malaysia, Thailand, China, Philippines, Sri Lanka, Vietnam, Indonesia, Mongolia, India, Laos, and Cambodia. According to the National Institute of Cancer Prevention and Research (NICPR), in 2018, in India total deaths due to cancer were 784,821.

These statistics determine an increase in the demand for advanced cancer diagnostics in various regions across the globe. Thus driving the growth of generic oncology drugs during the forecast period.

The market for generic cancer drugs is driven by frequent drug launches. Most of the major market players are involved in the manufacturing wide range of generic cancer drugs that help in reducing cost of cancer care. For instance, in July 2019, Lupin Pharmaceuticals, Inc. launched a generic Imatinib Mesylate tablets used to treat certain types of cancer.

Additionally April 2019, Emcure Pharmaceuticals, a leading pharmaceutical company from India launched world’s first generic Eribulin for treatment of metastatic breast cancer. 

Emcure is marketing the drug with brand name ‘Eribilin’, that offers high-quality and cost-effective treatment option to breast cancer patients in India. The medicine Eribilin is Eisai pharmaceutical’s generic version of expired patent product. 

Moreover, in January 2019, Hetero Healthcare Ltd launched a new generic Lapatinib tablets, which are used to treat metastatic breast cancer in India. The tablets are consumed along with Capecitabine or Letrozole, that together, inhibit the growth of cancer cells in patients. Thus, the constant developments in generic oncology drugs accelerate the market growth during the forecast period.

Generic drugs are copies of branded drugs. Their pharmacological effects are similar to the branded counterparts.

Generic drugs are cost effective as the manufacturers have not invested in the development and marketing a new drug.

When a drug patent expires, other manufacturers apply for FDA approval in order to manufacture and sell the product. Hence generic drugs are cheaper than branded drugs. The generic drug has exactly the same effects, dosage, side effects, route of administration, safety, risks, and strength as the original branded drug. 

Generic drugs are important in oncology as some anticancer drugs are only offered as generics. In most of the cases like, children with acute lymphoblastic leukemia or women patients with early-stage breast cancer are treated with generics. Generic drugs are extensively used in supportive care. The most significant benefit of using generic drugs is the cost, which is up to 85% less than that of a branded drug.


Molecular Type-Based Insights

In terms of molecular type, the Generic Oncology Drugs in healthcare market is segmented into large molecule, small molecule. In 2018, the small molecule segment held a largest market share of 87.67% of the generic oncology drugs market, by molecule type.

Generic Oncology Drugs in Healthcare Market, by Molecular Type – 2018 and 2027



Generic Oncology Drugs in Healthcare Market, by Molecular Type – 2018 and 2027

Get more information on this report :


Indication-Based Insights

Based on indication, the Generic Oncology Drugs in healthcare market is segmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, kidney cancer, cervical cancer, others. In 2018, the lung cancer segment held the largest share of the market, by indication.

Strategic Insights

Report Coverage - Generic Oncology Drugs Market
Report CoverageDetails
Market Size Value inUS$ 21,200.00 Million in 2018
Market Size Value byUS$ 36,029.60 Million by 2027
Growth rateCAGR of 6.3% from 2019-2027
Forecast Period2019-2027
Base Year2019
No. of Pages152
No. of Tables47
No. of Charts & Figures63
Historical data availableYes
Segments coveredMolecular Type ; Indication , and Geography
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

The Generic Oncology Drugs in healthcare market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

Generic Oncology Drugs in Healthcare Market – by Molecular Type

  • Large Molecule
  • Small Molecule

Generic Oncology Drugs in Healthcare Market – by Indication

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Kidney Cancer
  • Cervical Cancer
  • Others

Generic Oncology Drugs in Healthcare Market – by Geography

  • North America

    • US
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)

    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East & Africa (MEA)

    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South America and Central America (SCAM)

    • Brazil
    • Argentina
    • Rest of SCAM

Company Profiles

  • Teva Pharmaceutical Industries LTD.
  • Sandoz International GMBH
  • Glenmark Pharmaceuticals LIMITED
  • Sun Pharmaceutical Industries LTD
  • MSN Laboratories
  • Aurobindo Pharma
  • Intas Pharmaceuticals LTD
  • Zydus Cadila
  • Mylan N.V.
  • Shilpa Medicare LTD
  • Fresenius Kabi AG
  • Dr. Reddy’s Laboratories.

The List of Companies - Generic Oncology Drugs Market

  1. Teva Pharmaceutical Industries Ltd.
  2. Sandoz International GMBH
  3. Glenmark
  4. Sun Pharmaceutical Industries Ltd
  5. MSN Laboratories
  6. Aurobindo Pharma
  7. Intas Pharmaceuticals
  8. Zydus Cadila
  9. Mylan N.V.
  10. Cipla Inc.
  11. Fresenius Kabi AG
  12. Dr. Reddy’s Laboratories Ltd.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the generic oncology drugs market market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global generic oncology drugs market market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00006393
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




christmas_festive_offer

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000 $2700
  • $4550 $3640
  • $6550 $5240
  • $8550 $6840

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount